Modeling and simulation of biopharmaceutical performance

Area of Science:

• Pharmaceutical Sciences
• Biopharmaceutics
• Drug Regulatory Science

Background:

• Biopharmaceutical performance, influenced by formulation, is critical for drug bioavailability and effective dosing.
• Regulatory bodies focus on batch consistency, post-approval changes, and bioequivalence (BE) for generic drugs.

Purpose of the Study:

• To summarize biopharmaceutical modeling and simulation approaches used by the FDA's Office of Generic Drugs (OGD).
• To highlight the role of these methods in evaluating orally administered generic drugs.

Main Methods:

• Review of biopharmaceutical modeling and simulation practices within the FDA OGD.
• Focus on applications relevant to generic drug product assessment.

Main Results:

• Biopharmaceutical modeling and simulation are integral to the FDA OGD's regulatory framework.
• These tools support the evaluation of in vivo performance and bioequivalence of generic drugs.

Conclusions:

• Modeling and simulation are essential for ensuring the quality and performance of generic oral drug products.
• FDA OGD's utilization of these techniques aids in regulatory decision-making and patient safety.